Population-based screening for celiac disease: Improvement in morbidity and mortality from osteoporosis?

Archives of Internal Medicine

Volumn 165, Issue 4, 2005, Pages 370-372

  Buchman, Alan L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; GLUTEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LACTOSE; PARATHYROID HORMONE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; VITAMIN D;

BIOPSY; BONE DENSITY; BONE MASS; CALCIUM INTAKE; CELIAC DISEASE; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; ENDOSCOPY; EXERCISE; FRACTURE; GLUTEN FREE DIET; HIGH RISK POPULATION; HUMAN; LACTOSE INTOLERANCE; LIFESTYLE; MASS SCREENING; MORBIDITY; MORTALITY; OSTEOPENIA; OSTEOPOROSIS; PAIN; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; SEROLOGY; SYMPTOM; VITAMIN SUPPLEMENTATION;

CELIAC DISEASE; FEMALE; HUMANS; MALE; MASS SCREENING; MORBIDITY; OSTEOPOROSIS;

EID: 14044278802     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.4.370     Document Type: Editorial

References (30)

1. National Institutes of Health. Osteoporosis prevention, diagnosis, and therapy: National Institutes of Health Consensus Development Conference Statement, March 27-29, 2000. Available at: http://odp.od.nih.gov/consensus/ cons/111/111_intro .htm. Accessed December 28, 2004.
2. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108-1112.
3. Schettler AE, Gustafson EM. Osteoporosis prevention starts in adolescence. J Am Acad Nurse Pract. 2004;16:274-282.
4. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-289.
5. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231-236.
6. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051-1056.
7. Bjarnason NH, Sarker S, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int. 2001;12:922-930.
8. Center JR, Nguyen TV, Pocock NA, Eisman JA. Columetric bone density at the fermoral neck as a common measure of hip fracture risk for men and women. J Clin Endocrinol Metab. 2004;89:2776-2782.
9. Not T, Horvath K, Hill ID, et al. Celiac risk in the USA: High prevalence of antimysium antibodies in health blood donors. Scand J Gastroenterol. 1998;33:494-498.
10. Fasano A. Where have all the American celiacs gone? Acta Paediatr Suppl. 1996;412:20-24.
11. Stenson WF, Newberry R, Lorenz R, Baldus C, Civitelli R. Increased prevalence of celiac disease and need for routine screening among patients within osteoporosis. Arch Intern Med. 2005;165:393-399.
12. Alexandre C. Diagnosis and treatment of osteoporosis. Curr Opin Rheumatol. 1995;7:240-242.
13. Burgin-Wolff A, Dahlbom I, Hadziselimovic F, Petersson CJ. Antibodies against human tissue transglutaminase and endomysium in diagnosing and monitoring coeliac disease. Scand J Gastroenterol. 2002;37:685-691.
14. Freeman HJ. Strongly positive tissue transglutaminase antibody assays without celiac disease. Can J Gastroenterol. 2004;18:25-28.
15. Tommasini A, Not T, Kiren V, et al. Mass screening for coeliac disease using antihuman transglutaminase antibody assay. Arch Dis Child. 2004;89:512-515.
16. Cataldo F, Marino V, Ventura A, et al. Prevalence and clinical features of selective immunoglobulin A deficiency in celiac disease: an Italian multicentre study. Gut. 1998;42:362-365.
17. Weiss B, Bujanover Y, Avidan B, et al. Positive tissue transglutaminase antibodies with negative endomysial antibodies: low rate of celiac disease. Isr Med Assoc J. 2004;6:9-12.
18. Lock RJ, Stevens S, Pitcher MC, Unsworth DJ. Is immunoglobulin A anti-tissue transglutaminase antibody a reliable serological marker of coeliac disease? Eur J Gastroenterol Hepatol. 2004;16:467-470.
19. Sategna-Guidetti C, Grosso SB, Grosso S, et al. The effects of a 1-year gluten withdrawal on bone mass, bone metabolism and nutritional status in newly-diagnosed adult coeliac disease patients. Aliment Pharmacol Ther. 2000;14:35-43.
20. Kemppainen T, Kroger H, Janatuinen E, et al. Bone recovery after a gluten-free diet: a 5-year follow-up study. Bone. 1999;25:355-360.
21. Bai JC, Gonzalez D, Mautatlen C, et al. Long-term effect of gluten restriction on bone mineral density of patients with coeliac disease. Aliment Pharmacol Ther. 1997;11:157-164.
22. Mather KJ, Meddings JB, Beck PL, et al. Prevalence of IgA-antiendomysial antibody in asymptomatic low bone mineral density. Am J Gastroenterol. 2001;96:120-125.
23. Gonzalez D, Sugai E, Gomez JC, et al. Is it necessary to screen for celiac disease in postmenopausal osteoporotic women? Calcif Tissue Int. 2002;71:141-144.
24. Fisher AA, Davis MW, Budge MM. Should we screen adults with osteoporotic fractures for coeliac disease. Gut. 2004;53:154-158.
25. West J, Logan RFA, Card TR, Smith C, Hubbard R. Fracture risk in people with celiac disease: a population-based cohort study. Gastroenterology. 2003;125:429-436.
26. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 14,416 patients in Denmark. Am J Epidemiol. 2002;156:1-10.
27. Corazza GR, Di Sario A, Cecchetti R, et al. Influence of pattern of clinical presentation and of gluten-free diet on bone mass and metabolism in adult coeliac disease. Bone. 1996;18:525-530.
28. Moreno ML, Vazquez H, Mazure R, et al. Stratification of bone fracture risk in patients with celiac sprue. Clin Gastroenterol Hepatol. 2004;2:127-134.
29. Drummond FJ, Annis P, O'Sullivan K, et al. Screening for asymptomatic celiac disease among patients referred for bone densitometry measurement. Bone. 2003;33:970-974.
30. Mautalen C, Gonzalez D, Mazure R, et al. Effect of treatment on bone mass, mineral metabolism, and body composition in untreated celiac disease patients. Am J Gastroenterol. 1997;92:313-318.